PD
VRDN icon

Point72 (DIFC)’s Viridian Therapeutics VRDN Stock Holding History

Point72 (DIFC)’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-54
Closed -$761 – 1913
2025
Q2 		$761 Sell
54
-4,719
-99% -$64K ﹤0.01% 1443
2025
Q1 		$64.3K Buy
+4,773
New +$81.3K ﹤0.01% 1156

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Point72 (DIFC)'s VRDN Position: Q3 2025 in Review

Point72 (DIFC) sold out of Viridian Therapeutics (VRDN) in Q3 2025, closing a stake of 54 shares — an estimated $761 sold.

Point72 (DIFC) first reported a position in VRDN in Q1 2025 and held it in 2 quarters. The position peaked at $64.3K in Q1 2025. 169 funds tracked by Wall St. Rank hold VRDN as of Q3 2025.

  • Point72 (DIFC) reported no remaining Viridian Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Point72 (DIFC) sold 54 Viridian Therapeutics shares in Q3 2025, an estimated $761.
  • Point72 (DIFC) first reported a position in Viridian Therapeutics in Q1 2025 and held it in 2 quarters.
  • Point72 (DIFC)'s Viridian Therapeutics position peaked at $64.3K in Q1 2025.
  • 169 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.